Chewpaste with Fluoride

Description

The product is identified by the SPL code 34089-3. No specific description details are provided in the text.

Uses and Indications

This drug is indicated for the prevention of tooth decay.

There are no teratogenic effects associated with this drug. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

Adults and children over 6 years of age are advised to take 1 tablet orally, twice daily, specifically every morning and night. The tablet should not be swallowed whole; instead, it must be chewed thoroughly. After chewing, users should wet their toothbrush and brush normally to ensure proper oral hygiene.

For children under 6 years of age, it is essential to consult a healthcare professional prior to use.

Contraindications

There are no contraindications listed for the use of this product. It is important to evaluate each patient's individual circumstances and medical history when considering treatment options.

Warnings and Precautions

If ingested, immediate action is required; individuals should contact a poison control center or seek medical assistance without delay.

It is imperative to ensure that this product is stored out of reach of children to prevent accidental ingestion.

Currently, there are no specific laboratory tests or monitoring parameters associated with the safe use of this product. Healthcare professionals should remain vigilant and exercise clinical judgment in the absence of detailed laboratory guidance.

In the event of an adverse reaction or concerning symptoms, patients are advised to discontinue use and consult their healthcare provider for further evaluation and management.

Side Effects

Patients should be aware that if the product is swallowed, it is imperative to call a poison control center or seek medical assistance immediately. This warning highlights the potential seriousness of the situation and underscores the importance of prompt action in the event of accidental ingestion.

No additional adverse reactions, including serious or common reactions, have been specified in the provided data. Therefore, healthcare professionals should monitor patients for any unexpected effects and report them as necessary, considering the importance of patient safety and the need for comprehensive postmarketing surveillance.

Drug Interactions

There are no reported drug interactions associated with the use of this medication. Additionally, no interactions with laboratory tests have been identified. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Chewpaste with Fluoride (sodium fluoride). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 6 years and older may be administered 1 tablet, twice daily. For children under 6 years of age, it is advised to consult a healthcare professional prior to use.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

There is no specific information available regarding the use of this medication during pregnancy, including safety concerns, dosage modifications, or special precautions that should be taken. Healthcare professionals should consider the lack of data when prescribing this medication to pregnant patients and weigh the potential risks and benefits. Women of childbearing potential should be counseled on the absence of established safety data and the importance of discussing any potential pregnancy with their healthcare provider.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or any lactation considerations. Healthcare professionals should exercise caution and consider the potential risks and benefits when prescribing this medication to lactating mothers. Further research may be necessary to fully understand the implications for breastfed infants.

Renal Impairment

There is no information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution and consider the lack of specific guidance when prescribing to patients with reduced kidney function.

Hepatic Impairment

There is no information available regarding the use of this medication in patients with hepatic impairment. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions specified for individuals with compromised liver function. Healthcare professionals should exercise clinical judgment when considering the use of this medication in patients with liver problems, as the absence of specific guidance necessitates careful evaluation of the patient's overall health status and liver function.

Overdosage

In the event of an overdosage, immediate action is crucial. If the substance is ingested, it is imperative to contact a poison control center or seek medical assistance without delay.

Healthcare professionals should be aware of the potential symptoms associated with overdosage, which may vary depending on the specific substance involved. Prompt recognition of these symptoms is essential for effective management.

Management procedures should include a thorough assessment of the patient's condition, including vital signs and any presenting symptoms. Supportive care may be necessary, and specific interventions should be guided by the clinical scenario and the recommendations of poison control experts.

In all cases of suspected overdosage, timely intervention can significantly impact patient outcomes.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the understanding of the potential toxicological profile in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children to prevent accidental ingestion or misuse. It is important to emphasize the necessity of proper storage and handling to ensure the safety of young individuals.

Storage and Handling

The product is supplied in a tightly closed container to ensure its integrity. It is essential to store the product in a cool, dry place to maintain its quality and effectiveness. Proper storage conditions are crucial for preserving the product's stability and preventing degradation.

Additional Clinical Information

The medication is administered orally, with a recommended dosage of one tablet twice daily for adults and children over six years of age. Patients should not swallow the tablet whole; instead, they should chew it, wet their toothbrush, and brush normally. This process should be repeated every morning and night, and clinicians are advised to consult a healthcare professional before administering the medication to children under six years.

Patients should be counseled to seek immediate medical assistance or contact a poison control center if the tablet is swallowed. It is important to keep the medication out of reach of children and to avoid use if the seal is broken. No additional information is available regarding laboratory tests, abuse potential, or postmarketing experiences.

Drug Information (PDF)

This file contains official product information for Chewpaste with Fluoride, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)